Pioneer of Etanercept Treatment is Keynote Speaker for Drug Summit
Maybe the scientific community is becoming more open-minded after all. Dr. Edward Tobinick -- pioneer of perispinal etanercept treatment for Alzheimer's disease -- will be the keynote speaker at Cambridge Healthtech Institute's Third Annual Drug Repositioning Summit on Monday, October 6 in Boston, Massachusetts.This is a perfect fit for Dr. Tobinick, whose research has led to the "repositioning" of etanercept (Enbrel) -- a drug already FDA-approved for treatment of rheumatoid arthritis, psoriasis, and related conditions -- into a treatment for Alzheimer's disease and other dementias.
His research, which has shown promising results, has been published in several peer-reviewed journals. However, his call for assistance in organizing large-scale clinical trials has been met with resistance by major research organizations and Amgen, the maker of Enbrel. This is puzzling, considering that current FDA-approved treatments for Alzheimer's are only moderately effective. A better treatment -- or more preferably, a cure -- must be found before the rise in Alzheimer's cases threatens to bankrupt our already troubled health care system.
That's why I'm so pleased to see that Dr. Tobinick has been invited to speak at this important summit. It means that more scientists and physicians will hear about his treatment and perhaps be inspired to pool their resources to give perispinal etanercept for Alzheimer's the clinical trial it deserves.
Previous blogs about etanercept:
- Etanercept Treatment for Alzheimer's Featured on National News Program
- Etanercept Research Continues to Spawn Hope, Criticism
Photo of Enbrel © Gold Standard
Comments
Thank you again Carrie for bringing Dr. Tobinick’s research to the forefront. I was at his office today with my Mom, and everyone there was very excited and hopeful that this will be the start of getting FDA approval for Enbrel for Alzheimer’s, so that medicare and/or insurance will help pay for the treatment.
No matter what anyone thinks, Dr. Tobinick is trying hard to get this going. He was stopped in his tracks by Amgen, so he had to take this a whole different route than usual. Hardly anyone knows the real conflicts he has gone through.
Bottom line, this treatment works for most of the patients he has treated. My Mom was doing fine, but had to stop for an unexpected surgery. In the month where we had to stop the treatments, and because of the trauma of blood loss and surgery, Mom was back to square one at the beginning of August. We started the treatments again on Aug. 4, and this time it’s been slow, but she is recovering, and it is with the help of the treatment that she even had a chance.
Thank you Dr. Tobinick and all your staff. You all are wonderful, and you make my Mom smile.
Felicia